https://www.eurekalert.org/news-releases/963106
A paper published in Science Bulletin described the analysis result of a multinational, multicenter, randomized, double-blind, treat-to-target, phase 3 trial to evaluate the efficacy and safety of Ultra rapid lispro (URLi) in adults with type 2 diabetes (T2D)…
Create an account or login to join the discussion